Results 61 to 70 of about 81,406 (283)
Triple‐negative breast cancer (TNBC) faces significant treatment challenges due to its resistance to chemotherapy and high‐rate metastatic occurrence.
Faaza Aulia Rahman +5 more
doaj +1 more source
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. [PDF]
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk.
Aalfs, Cora M +99 more
core
Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. [PDF]
In this issue of Cancer Cell, Hydbring and colleagues define a novel class of microRNAs (miRNAs), deemed cell-cycle-targeting miRNAs, that target several cyclins/CDKs, reduce tumor cell growth, and induce apoptosis.
Knudsen, Karen E., Schiewer, Matthew J.
core +2 more sources
An introduction for multidrive and environment‐adaptive micro/nanorobotics: design and fabrication strategies, intelligent actuation, and their applications. Various intelligent actuation approaches—magnetic, acoustic, optical, chemical, and biological—can be synergistically designed to enhance flexibility and adaptive behavior for precision medicine ...
Aiqing Ma +10 more
wiley +1 more source
Breast cancer represents the highest number of cancer cases in Indonesia, with triple‐negative breast cancer (TNBC) being a common subtype (10–15%). MicroRNAs play a role in cancer epigenetics and contributing as core factors to the disease.
Fita Nilasari +3 more
doaj +1 more source
Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. [PDF]
Triple Negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2.
Austin, David +5 more
core +1 more source
Cytotoxicity of the urokinase-plasminogen activator inhibitor carbamimidothioic acid (4-boronophenyl) methyl ester hydrobromide (BC-11) on triple-negative MDA-MB231 breast cancer cells [PDF]
: BC-11 is an easily synthesized simple thiouronium-substituted phenylboronic acid, which has been shown to be cytotoxic on triple negative MDA-MB231 breast cancer cells by inducing a perturbation of cell cycle when administered at a concentration equal ...
Baltus, Christine B +5 more
core +2 more sources
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source
Multiphoton Imaging of Labeled Breast Cancer Cells to Quantify Intra and Extracellular Receptors [PDF]
Every year 200,000 women in the United States are diagnosed with breast cancer. Of the cases diagnosed, 10% -15% are classified as triple negative breast cancer (TNBC) due to the absence of estrogen, progesterone, and HER-2/Neu receptors.
Wiggins, Sydney C
core +2 more sources
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) [PDF]
Every 2 years, the International Consensus Conference on the Treatment of Primary Breast Cancer takes place in St. Gallen. Given that the concept of the St.
Beckmann, Matthias W. +27 more
core +1 more source

